GILD Gilead Sciences margins

Relative Growth: Rel. Growth: 51

Relative Strength: Rel. Strength: 66

Relative Valuation: Rel. Valuation: 12

Relative Profitability: Rel. Profitability: 30

Gross margin

79.6%

Operating margin

-8.2%

EBITDA margin

5.9%

Net margin

-10.6%

Gilead Sciences reports a gross margin of 79.6%, an operating margin of -8.2%, an EBITDA margin of 5.9%, and a net margin of -10.6%, while its operating margin is negative at -8.2%, and its net margin is negative at -10.6%. Gross margin increased the most, by 1.1 percentage points, while operating margin fell the most, by 36.1 percentage points.

GILD margin history

Gross, operating, EBITDA and net margin trends

Over the last 3 years, Gilead Sciences's margins averaged 77.83% gross, 19.59% operating, 30.53% EBITDA, and 14.16% net. Currently, gross margin is above its three-year average, while operating, EBITDA, and net margins are below their three-year averages.

GILD margin expansion

Year-over-year margin changes in percentage points

Gilead Sciences's gross margin expanded by 1.1 percentage points, but operating margin contracted by 36.1 percentage points, EBITDA margin by 32.1 percentage points, and net margin by 32.5 percentage points.

Gross margin expansion

1.1pp

Operating margin expansion

-36.1pp

EBITDA margin expansion

-32.1pp

Net margin expansion

-32.5pp

GILD Gross margin

Gilead Sciences's gross margin averaged 77.83% during the last 3 years. Compared with its three-year average, Gilead Sciences's current gross margin is 79.6% and is 1.8 percentage points above its three-year average. Over the last 3 years, Gilead Sciences's gross margin peaked at 79.6% in Jun 2026 and reached a low of 75.7% in Jun 2024.

GILD Operating margin

Gilead Sciences recorded an average operating margin of 19.59% across the last 3 years. At present, the current operating margin for Gilead Sciences is -8.2%, 27.8 percentage points below its three-year average. The operating margin for Gilead Sciences moved between -8.2% in Jun 2026 and 36.1% in Sep 2025.

GILD EBITDA margin

Gilead Sciences recorded an average EBITDA margin of 30.53% across the last 3 years. Gilead Sciences's current EBITDA margin is 5.9% and is 24.6 percentage points below its three-year average. The EBITDA margin for Gilead Sciences moved between 5.9% in Jun 2026 and 48.7% in Mar 2026.

GILD Net margin

Over the last 3 years, Gilead Sciences's net margin averaged 14.16%. The current net margin of -10.6% is 24.8 percentage points below its three-year average. During this period, net margin reached a high of 31% in Mar 2026 and a low of -10.6% in Jun 2026.

GILD margin group comparison

Margins compared with peer-group, industry and sector averages

Gilead Sciences's gross margin of 79.6% is above the Healthcare sector, the industry and its peers average. Compared to its Healthcare sector average of 68.5%, Gilead Sciences's gross margin is 16% higher.

GILD margin peer comparison

Compare margins with selected peers

Frequently asked questions

What is Gilead Sciences's gross margin?

As of Jun 30, 2026, GILD has a gross margin of 79.6%.

What is Gilead Sciences's operating margin?

For the period ending Jun 30, 2026, GILD recorded an operating margin of -8.2%.

What is Gilead Sciences's EBITDA margin?

The current EBITDA margin for GILD is 5.9% as of Jun 30, 2026.

What is Gilead Sciences's net margin?

For the period ending Jun 30, 2026, GILD recorded a net margin of -10.6%.

What are the average margins of GILD?

Gilead Sciences's gross, operating, EBITDA, and net margins averaged 77.8% gross, 19.6% operating, 30.5% EBITDA, and 14.2% net over the last 3 years.

What are the highest historical margins of GILD?

Over the last 5 years, Gilead Sciences's highest margins were 80.5% gross in Sep 2021, 42.3% operating in Sep 2021, 48.7% EBITDA in Mar 2026, and 31% net in Mar 2026.

What are the lowest historical margins of GILD?

Within the 5-year period, GILD recorded its lowest margins at 74.6% gross in Sep 2022, -8.2% operating in Jun 2026, 5.9% EBITDA in Jun 2026, and -10.6% net in Jun 2026.